3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
Head & Neck
2
Gastrointestinal
2
Thoracic
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
20
Triple Negative Breast Neoplasms
14
Ovarian Neoplasms
7
Melanoma
7
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
5
Neoplasm Metastasis
5
Carcinoma, Renal Cell
5
Stomach Neoplasms
4
Pancreatic Neoplasms
4
Head and Neck Neoplasms
4
Carcinoma, Transitional Cell
4
Uterine Cervical Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Sarcoma
3
Endometrial Neoplasms
3
Carcinoma, Hepatocellular
3
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Multiple Myeloma
2
Mesothelioma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lung Neoplasms
2
Liver Neoplasms
2
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
2
Leukemia, Myeloid, Acute
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Interventions
pembrolizumab
3
Trastuzumab
2
Irinotecan
2
Drug Therapy
2
Cisplatin
2
Capecitabine
2
tivozanib
1
tipifarnib
1
spartalizumab
1
seribantumab
1
pertuzumab
1
entinostat
1
atezolizumab
1
Thalidomide
1
Ritonavir
1
Quality of Life
1
Peripheral Blood Stem Cell Transplantation
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Observation
1
Molecular Diagnostic Techniques
1
Mesna
1
Magnetic Resonance Spectroscopy
1
Itraconazole
1
Ipilimumab
1
Interleukin-12 Subunit p35
1
Interleukin-12
1
Injections, Subcutaneous
1
Immunotherapy
1
Ifosfamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bile Duct Neoplasms
×
Ipilimumab
×
Breast
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts